Home
Live Updates
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer : comparemela.com
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and Drug Administration approval represents a...
Related Keywords
Switzerland ,
Singapore ,
Australia ,
United Kingdom ,
Canada ,
Nick Montemarano ,
Daniel Faga ,
Tesaro Inc ,
Exchange Commission ,
Nasdaq ,
Strategic Communications ,
Drug Administration ,
Oncology Center ,
European Medicines Agency ,
Anaptysbio Inc ,
Biologics License Application ,
Priority Review ,
Drug User Fee Act ,
Exclusive License Agreement ,
Sagard Healthcare Royalty Partners ,
Excellence Project Orbis Framework ,
Project Orbis ,
European Medicines ,
Response Evaluation Criteria ,
Solid Tumors ,
Breakthrough Therapy ,
Private Securities Litigation Reform Act ,
Investor Relations ,
Markets ,
comparemela.com © 2020. All Rights Reserved.